Micro
Aftermath
Active
Approvazione da parte della FDA di una dose più elevata di Wegovy da parte di Novo Nordisk
Activity declining — narrative losing relevance.
Punteggio
0,3
Velocità
▲ 0,0
Articoli
14
Fonti
3
Sentiment Timeline
Event Timeline
Apr 02, 2026
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Bullish
Apr 01, 2026
Novo Nordisk's Wegovy Approved For Cardiovascular Event Risk Reduction In England
Bullish
Mar 31, 2026
Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries …
Neutral
Mar 20, 2026
Are GLP-1s tax deductible? How to deduct Ozempic, Wegovy, and other weight-loss …
Neutral
Articoli Correlati
Novo Nordisk's Wegovy Approved For Cardiovascular Event Risk Reduction In England
Nasdaq
·
Apr 01, 2026
Could This New Approval Be a Turning Point For Novo Nordisk?
Nasdaq
·
Apr 01, 2026
India is launching cheap, weight-loss drugs and Novo Nordisk is betting on its brands to …
CNBC
·
Mar 23, 2026
This Hims & Hers Move Could Destroy Competitors
Nasdaq
·
Mar 21, 2026
Down Near Its 5-Year Low, Is Novo Nordisk Stock Too Cheap to Pass Up?
Nasdaq
·
Mar 20, 2026
Are GLP-1s tax deductible? How to deduct Ozempic, Wegovy, and other weight-loss drugs.
Yahoo Finance
·
Mar 20, 2026
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to …
CNBC
·
Mar 19, 2026
Cronologia
Prima apparizioneMar 19, 2026
Ultimo aggiornamentoMar 19, 2026